378 related articles for article (PubMed ID: 18381567)
1. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
; Alexander JH; Emery RW; Carrier M; Ellis SJ; Mehta RH; Hasselblad V; Menasche P; Khalil A; Cote R; Bennett-Guerrero E; Mack MJ; Schuler G; Harrington RA; Tardif JC
JAMA; 2008 Apr; 299(15):1777-87. PubMed ID: 18381567
[TBL] [Abstract][Full Text] [Related]
2. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
Tardif JC; Carrier M; Kandzari DE; Emery R; Cote R; Heinonen T; Zettler M; Hasselblad V; Guertin MC; Harrington RA;
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1604-11. PubMed ID: 17532963
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
Mehta RH; Alexander JH; Emery R; Ellis SJ; Hasselblad V; Khalil A; Carrier M; Harrington RA; Tardif JC;
Am Heart J; 2008 Apr; 155(4):600-8. PubMed ID: 18371465
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
Carrier M; Emery R; Kandzari DE; Harrington R; Guertin MC; Tardif JC
J Cardiovasc Surg (Torino); 2008 Apr; 49(2):249-53. PubMed ID: 18431346
[TBL] [Abstract][Full Text] [Related]
5. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; Malloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH;
JAMA; 2004 May; 291(19):2319-27. PubMed ID: 15150203
[TBL] [Abstract][Full Text] [Related]
6. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.
Newman MF; Ferguson TB; White JA; Ambrosio G; Koglin J; Nussmeier NA; Pearl RG; Pitt B; Wechsler AS; Weisel RD; Reece TL; Lira A; Harrington RA;
JAMA; 2012 Jul; 308(2):157-64. PubMed ID: 22782417
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
[TBL] [Abstract][Full Text] [Related]
8. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial).
Kandzari DE; Labinaz M; Cantor WJ; Madan M; Gallup DS; Hasselblad V; Joseph D; Allen A; Green C; Hidinger KG; Krucoff MW; Christenson RH; Harrington RA; Tcheng JE
Am J Cardiol; 2003 Sep; 92(6):660-4. PubMed ID: 12972102
[TBL] [Abstract][Full Text] [Related]
9. Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery.
van Diepen S; Merrill PD; Carrier M; Tardif JC; Podgoreanu M; Alexander JH; Lopes RD
J Thromb Thrombolysis; 2017 May; 43(4):446-453. PubMed ID: 28194628
[TBL] [Abstract][Full Text] [Related]
10. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial.
Burns KE; Chu MW; Novick RJ; Fox SA; Gallo K; Martin CM; Stitt LW; Heidenheim AP; Myers ML; Moist L
JAMA; 2005 Jul; 294(3):342-50. PubMed ID: 16030279
[TBL] [Abstract][Full Text] [Related]
11. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
Anesthesiology; 1995 Oct; 83(4):658-73. PubMed ID: 7574044
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel treatment and the MEND-CABG II trial.
Oh J; Hong N; Kang SM
JAMA; 2008 Sep; 300(9):1021; author reply 1021-2. PubMed ID: 18768409
[No Abstract] [Full Text] [Related]
13. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
[TBL] [Abstract][Full Text] [Related]
14. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
Mangano DT
JAMA; 1997 Jan 22-29; 277(4):325-32. PubMed ID: 9002496
[TBL] [Abstract][Full Text] [Related]
15. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine.
Mangano DT; Miao Y; Tudor IC; Dietzel C; ;
J Am Coll Cardiol; 2006 Jul; 48(1):206-14. PubMed ID: 16814669
[TBL] [Abstract][Full Text] [Related]
16. Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
Yau JM; Alexander JH; Hafley G; Mahaffey KW; Mack MJ; Kouchoukos N; Goyal A; Peterson ED; Gibson CM; Califf RM; Harrington RA; Ferguson TB;
Am J Cardiol; 2008 Sep; 102(5):546-51. PubMed ID: 18721510
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.
Schulze CJ; Castro MM; Kandasamy AD; Cena J; Bryden C; Wang SH; Koshal A; Tsuyuki RT; Finegan BA; Schulz R
Crit Care Med; 2013 Nov; 41(11):2512-20. PubMed ID: 23928836
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH; Hafley G; Harrington RA; Peterson ED; Ferguson TB; Lorenz TJ; Goyal A; Gibson M; Mack MJ; Gennevois D; Califf RM; Kouchoukos NT;
JAMA; 2005 Nov; 294(19):2446-54. PubMed ID: 16287955
[TBL] [Abstract][Full Text] [Related]
19. Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
Liakopoulos OJ; Kuhn EW; Hellmich M; Kuhr K; Krause P; Reuter H; Thurat M; Choi YH; Wahlers T;
Am Heart J; 2015 Jul; 170(1):46-54, 54.e1-2. PubMed ID: 26093863
[TBL] [Abstract][Full Text] [Related]
20. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
